Neutrophil activity in serum as a biomarker for multiple sclerosis

Multiple Sclerosis (MS) is an immune-mediated inflammatory disease affecting the central nervous system (CNS). Current treatments target neuroinflammation, but only limit the disease progression by reducing brain atrophy and a worsening in neurodegenerative damage. A blood-based biomarker of neutrophil activity, CPa9-HNE, holds the potential as a diagnostic biomarker in MS. We evaluated the CPa9-HNE biomarker in healthy donors, and patients with primary progressive MS (PPMS) and relapsing/remitting MS (RRMS). The CPa9-HNE was able to discriminate between the healthy donors and PPMS and RPMS with an AUROC>0.97. The CPa9-HNE biomarker may be used to assess patients’ eligibility for targeted treatments.